Insilico Medicine
Founded Year
2014Stage
Series E | AliveTotal Raised
$512MValuation
$0000Last Raised
$110M | 3 mos agoRevenue
$0000Mosaic Score The Mosaic Score is an algorithm that measures the overall financial health and market potential of private companies.
-55 points in the past 30 days
About Insilico Medicine
Insilico Medicine is a biotechnology company that focuses on artificial intelligence in drug discovery and development. The company provides AI platforms for multi-omics target discovery, deep biology analysis, automated drug design, and predicting outcomes in clinical trials. The technologies are intended to assist in the process of discovering and developing new medications for various diseases. It was founded in 2014 and is based in Pudong, China.
Loading...
Insilico Medicine's Product Videos
ESPs containing Insilico Medicine
The ESP matrix leverages data and analyst insight to identify and rank leading companies in a given technology landscape.
The healthcare humanoid robots market focuses on developing robots that assist in medical settings by performing tasks such as patient interaction, monitoring, and logistics support. These robots enhance healthcare services in hospitals and elderly care facilities by aiding professionals and improving operational efficiency. The market is growing due to increasing healthcare demands and advancemen…
Insilico Medicine named as Challenger among 5 other companies, including Tencent, Fourier, and Figure.
Insilico Medicine's Products & Differentiators
Pharma.AI
Global’s first end-to-end generative Al software and robotics platform designed to improve the quality and productivity of pharmaceutical research, currently commercially-available
Loading...
Research containing Insilico Medicine
Get data-driven expert analysis from the CB Insights Intelligence Unit.
CB Insights Intelligence Analysts have mentioned Insilico Medicine in 14 CB Insights research briefs, most recently on Mar 11, 2025.
Jan 11, 2024
The generative AI in healthcare market map
Jan 8, 2024
4 applications of generative AI in drug R&D
Expert Collections containing Insilico Medicine
Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.
Insilico Medicine is included in 7 Expert Collections, including AI 100.
AI 100
199 items
Winners of CB Insights' annual AI 100, a list of the 100 most promising AI startups in the world.
Artificial Intelligence
9,962 items
Companies developing artificial intelligence solutions, including cross-industry applications, industry-specific products, and AI infrastructure solutions.
Digital Health 50
150 items
The winners of the second annual CB Insights Digital Health 150.
Digital Health
11,305 items
The digital health collection includes vendors developing software, platforms, sensor & robotic hardware, health data infrastructure, and tech-enabled services in healthcare. The list excludes pureplay pharma/biopharma, sequencing instruments, gene editing, and assistive tech.
Drug Discovery Tech Market Map
221 items
This CB Insights Tech Market Map highlights 220 drug discovery companies that are addressing 12 distinct technology priorities that pharmaceutical companies face.
Generative AI
1,298 items
Companies working on generative AI applications and infrastructure.
Insilico Medicine Patents
Insilico Medicine has filed 70 patents.
The 3 most popular patent topics include:
- transcription factors
- proteins
- clusters of differentiation
Application Date | Grant Date | Title | Related Topics | Status |
|---|---|---|---|---|
7/6/2023 | 2/18/2025 | Trifluoromethyl compounds, Transcription factors, Designer drugs, Prodrugs, Cannabinoids | Grant |
Application Date | 7/6/2023 |
|---|---|
Grant Date | 2/18/2025 |
Title | |
Related Topics | Trifluoromethyl compounds, Transcription factors, Designer drugs, Prodrugs, Cannabinoids |
Status | Grant |
Latest Insilico Medicine News
Mar 24, 2025
Modern Dental Group and Insilico Medicine keen to use city’s unrivalled global connections to create a healthier world In partnership with:Belt and Road Office Reading Time:4 minutes Published: 1:00pm, 24 Mar 2025 Hong Kong is keen to foster its medical and health industries and position the city as a global hub for technology and innovation as it offers world-class research and development (R&D) infrastructure, a strong talent pool and many favourable policies and incentives for companies in these industries. Advertisement Chief Executive John Lee Ka-chiu announced a series of initiatives during last year’s policy address – the annual platform used to chart the Hong Kong government’s plans for the future – to support the city into an international health and medical innovation centre. Hong Kong businesses are already forging ahead in providing healthcare services to partners around the world by making use of the city’s position as a functional platform for China’s Belt and Road Initiative. This plan aims to encourage collaboration among participating countries in fields such as trade, infrastructure, innovation, digitalisation, green development and healthcare. Companies that are leading the charge in global healthcare collaboration include Modern Dental Group and Insilico Medicine. Modern Dental Group, a dental prosthetic device provider and distributor, which was founded in Hong Kong in 1986, has operations around the world, including in mainland China, Southeast Asia, Europe, Australia and Africa. In 2023, the company reached the milestone of helping 2 million patients. Advertisement The company continues to leverage Hong Kong’s unique advantage as a gateway between China and the world to expand its business. It recently acquired Hexa Ceram Dental Laboratory, one of Thailand’s largest dental laboratories, and opened a production facility in Vietnam. These new premises have enabled the company to offer dental prosthetics at more affordable prices. Advertisement
Insilico Medicine Frequently Asked Questions (FAQ)
When was Insilico Medicine founded?
Insilico Medicine was founded in 2014.
Where is Insilico Medicine's headquarters?
Insilico Medicine's headquarters is located at Lane 2889, Jinke Road, Pudong New Area, Pudong.
What is Insilico Medicine's latest funding round?
Insilico Medicine's latest funding round is Series E.
How much did Insilico Medicine raise?
Insilico Medicine raised a total of $512M.
Who are the investors of Insilico Medicine?
Investors of Insilico Medicine include Warburg Pincus, OrbiMed Advisors, Value Partners, Puxing Synergy Fund, Xiyi Venture Capital and 34 more.
Who are Insilico Medicine's competitors?
Competitors of Insilico Medicine include Variational AI, Aqemia, Cradle, Exscientia, Turbine and 7 more.
What products does Insilico Medicine offer?
Insilico Medicine's products include Pharma.AI and 1 more.
Who are Insilico Medicine's customers?
Customers of Insilico Medicine include Exelixis, Stemline Therapeutics , Sanofi, Fosun Pharma and Tenacia.
Loading...
Compare Insilico Medicine to Competitors
Atomwise develops machine learning-based discovery engines and uses artificial intelligence (AI)-based neural networks to help discover new medicines. It predicts drug candidates for pharmaceutical companies, start-ups, and research institutions and designs drugs using computational drug design. It was formerly known as Chematria. The company was founded in 2012 and is based in San Francisco, California.
Cradle operates in protein engineering within the biotechnology sector. The company has a platform that employs machine learning to design variants of protein sequences, aiding the protein engineering process for various applications such as therapeutics, chemicals, materials, and food. Cradle's services are aimed at biotech teams involved in research and development projects. It was founded in 2021 and is based in Amsterdam, Netherlands.
InstaDeep focuses on delivering artificial intelligence (AI)-powered decision-making systems for various enterprise sectors. The company offers solutions that leverage computing, deep learning, and reinforcement learning to address challenges in industries such as biology, logistics, electronic design, and energy. Its products and services are designed to help the capabilities of businesses by providing advanced AI tools and research insights. InstaDeep was formerly known as Digital Ink Group. It was founded in 2014 and is based in London, United Kingdom.
Aqemia focuses on transforming the drug discovery process. The company offers technology that combines quantum-inspired physics and machine learning to scale the drug discovery process, generating a rapidly growing pipeline of new drug candidates. It primarily sells to the pharmaceutical industry. It was founded in 2019 and is based in Paris, France.
Variational AI is a company focused on drug discovery utilizing generative AI within the biopharmaceutical sector. The company offers Enki, a platform that generates novel drug-like small molecules based on user-defined therapeutic product profiles (TPP) without requiring prior data. Variational AI primarily serves the biopharmaceutical industry, collaborating with partners to develop new therapeutics. It was founded in 2019 and is based in Vancouver, Canada.
YDS Pharmatech is a company focused on drug discovery in the pharmaceutical industry. The company offers a platform for the design of new drug candidates, utilizing structure-based de novo drug design and evolutionary AI to accelerate the drug discovery process. YDS Pharmatech primarily serves the pharmaceutical industry. It was founded in 2020 and is based in Albany, New York.
Loading...